SEHK:2268Life Sciences
Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership
Akari Therapeutics has entered a partnership with WuXi XDC Cayman (SEHK:2268) to support development of Akari’s PH1 payload and AKTX-101 program for metastatic urothelial cancer, further linking WuXi XDC to next generation ADC platforms.
See our latest analysis for WuXi XDC Cayman.
Investors appear to be weighing WuXi XDC’s new ADC partnership against a mixed share price pattern. The 30 day share price return of 3.64% contrasts with a 90 day share price return decline of 13.75% and a 1 year...